SCOPUS 정보 검색 플랫폼

Community Oncology

Volumn 8, Issue 8, 2011, Pages 357-369

Mechanisms of action of commonly used drugs to treat cancer

(2) Trigg, Michael E a Flanigan Minnick, Anne b

a MERCK RESEARCH LABORATORIES (United States)

b THOMAS JEFFERSON UNIVERSITY (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; ALKYLATING AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BLEOMYCIN; CHLORMETHINE DERIVATIVE; CISPLATIN; DACARBAZINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; EPIGENETIC AGENT; ERLOTINIB; ETOPOSIDE; FOLIC ACID ANTAGONIST; IFOSFAMIDE; IMMUNOMODULATING AGENT; MELPHALAN; MITOXANTRONE; NAVELBINE; NITROSOUREA DERIVATIVE; OXALIPLATIN; PACLITAXEL; PYRIMIDINE DERIVATIVE; SIGNAL TRANSDUCTION INHIBITOR; SORAFENIB; TAMOXIFEN; TAMOXIFEN CITRATE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT;

CANCER COMBINATION CHEMOTHERAPY; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG TARGETING; EPIGENETICS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; PRESCRIPTION; REVIEW;

EID: 80052717017 PISSN: 15485315 EISSN: None Source Type: Journal
DOI: 10.1016/S1548-5315(12)70051-7 Document Type: Review

Times cited : (6)

References (88)

1
- 0004004276
- eds, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins
- Chabner BA, Longo DL [eds]. Cancer Chemotherapy and Biotherapy: Principles and Practice, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
- (2006) Cancer Chemotherapy and Biotherapy: Principles and Practice
- Chabner, B.A.¹ Longo, D.L.²

2
- 77749239979
- Targeted therapies in cancer
- Ciavarella S, Milano A, Dammacco F, Silvestris F. Targeted therapies in cancer. Bio-Drugs 2010;24:77-88.
- (2010) Bio-Drugs , vol.24 , pp. 77-88
- Ciavarella, S.¹ Milano, A.² Dammacco, F.³ Silvestris, F.⁴

3
- 2342631260
- Translating cancer genomics into clinical oncology
- Ramaswamy S. Translating cancer genomics into clinical oncology. N Engl J Med 2004;350:1814-1816.
- (2004) N Engl J Med , vol.350 , pp. 1814-1816
- Ramaswamy, S.¹

4
- 84863329050
- Cancer Facts and Figures 2010, Accessed July 15
- Cancer Facts and Figures 2010. American Cancer Society. http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf. Accessed July 15, 2011.
- (2011) American Cancer Society

5
- 40749120515
- Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy
- Blansfield JA, Caragacianu D, Alexander HR, et al. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 2008;14:270-280.
- (2008) Clin Cancer Res , vol.14 , pp. 270-280
- Blansfield, J.A.¹ Caragacianu, D.² Alexander, H.R.³

6
- 34247362067
- Reimbursement for cancer agents: Coverage of off-label drug indications
- American Society of Clinical Oncology
- American Society of Clinical Oncology. Reimbursement for cancer agents: cover- age of off-label drug indications. J Clin Oncol 2006;24:3206-3208.
- (2006) J Clin Oncol , vol.24 , pp. 3206-3208

7
- 80052707023
- Current pharmacology of alkylating agents (Appendix 56-1)
- eds, 5th ed. Philadelphia, PA: Churchill Livingstone Elsevier
- Hoffman R, Benz J, Shattil SJ, et al [eds]. Current pharmacology of alkylating agents (Appendix 56-1). In: Hematology: Basic Principles and Practice, 5th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2009.
- (2009) Hematology: Basic Principles and Practice
- Hoffman, R.¹ Benz, J.² Shattil, S.J.³

8
- 85038523751
- Mustargen [package insert]. Whitehouse Station, NJ: Merck & Co, Inc.; 1999, Accessed July 15
- Mustargen [package insert]. Whitehouse Station, NJ: Merck & Co, Inc.; 1999. http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/06695slr031_mustargen_lbl.pf. Accessed July 15, 2011.
- (2011)

9
- 85038512837
- Leukeran [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2006, Accessed July 15
- Leukeran [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2006. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/010669s030lbl.pdf. Accessed July 15, 2011.
- (2011)

10
- 85038498539
- Alkeran [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2004, Accessed July 15
- Alkeran [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2004. http://www.celgene.com/pdfs/AlkeranPI_Tablet.pdf. Accessed July 15, 2011.
- (2011)

11
- 85038506398
- Ifex [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2007, Ac-cessed July 15
- Ifex [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2007. http://packageinserts.bms.com/pi/pi_ifex.pdf. Accessed July 15, 2011.
- (2011)

12
- 84860460071
- NCI Drug Dictionary
- NCI Drug Dictionary. Nation- al Cancer Institute. National Institutes of Health. http://www.cancer.gov/drugdictionary??CdrID=39748.
- Nation- Al Cancer Institute. National Institutes of Health

13
- 85038502870
- Cyclophosphamide. Wikipedia, Accessed July 15
- Cyclophosphamide. Wikipedia. http://en.wikipedia.org/wiki/Cyclophosphamide. Accessed July 15, 2011.
- (2011)

14
- 85038514730
- Cytoxan [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2005, Accessed July 15
- Cytoxan [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2005. http://packageinserts.bms.com/pi/pi_cytoxan.pdf. Accessed July 15, 2011.
- (2011)

15
- 85038493596
- BiCNU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011, Accessed July 15
- BiCNU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011. http://packageinserts.bms.com/pi/pi_bicnu.pdf. Accessed July 15, 2011.
- (2011)

16
- 85038522642
- Cisplatin [package insert]. Bedford, OH: Bedford Laboratories; 2004, Accessed July 15
- Cisplatin [package insert]. Bedford, OH: Bedford Laboratories; 2004. http://www.bedfordlabs.com/BedfordLabsWeb/products/inserts/CIS-AQ-P01.pdf. Accessed July 15, 2011.
- (2011)

17
- 85038498493
- Carboplatin. Drugs.com, Accessed July 15
- Carboplatin. Drugs.com. http://www.drugs.com/pro/carboplatin.html. Accessed July 15, 2011.
- (2011)

18
- 85038507706
- Carboplatin [package insert]. Irvine, CA: Spectrum Laboratories; 2005, Accessed July 15
- Carboplatin [package insert]. Irvine, CA: Spectrum Laboratories; 2005. http://www.spectrumpharm.com/drug_info/7003_05-2005.pdf. Accessed July 15, 2011.
- (2011)

19
- 85038509030
- Paraplatin [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2010, Accessed July 15
- Paraplatin [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2010. http://packageinserts.bms.com/pi/pi_parapla-tin.pdf. Accessed July 15, 2011.
- (2011)

20
- 85038505419
- Eloxatin [package insert]. Bridgewater, NJ: sanofi-aventis U.S.; 2009, Accessed July 15
- Eloxatin [package insert]. Bridgewater, NJ: sanofi-aventis U.S.; 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021492s011,021759s009lbl.pd. Accessed July 15, 2011.
- (2011)

21
- 85038524807
- Dacarbazine [package insert]. Bedford, OH: Bedford Laboratories; 2007, Accessed July 15
- Dacarbazine [package insert]. Bedford, OH: Bedford Laboratories; 2007. http://www.bedfordlabs.com/products/inserts/DCZ-P02.pdf. Accessed July 15, 2011.
- (2011)

22
- 85038511337
- Dacarbazine. Wikipedia, Accessed July 25
- Dacarbazine. Wikipedia. http://en.wikipedia.org/wiki.Dacarbazine. Accessed July 25, 2010.
- (2010)

23
- 85038499115
- Temodar [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2011, Accessed July 15
- Temodar [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2011. http://www.spfiles.com/pitemodar.pdf. Accessed July 15, 2011.
- (2011)

24
- 85038496313
- Poly (ADP-ribosyl)ation. Boston, MA: Landes Bioscience and Springer Science + Business Media, Inc.; 2006
- Burkle A. Poly (ADP-ribosyl)ation. Boston, MA: Landes Bioscience and Springer Science + Business Media, Inc.; 2006.
- Burkle, A.¹

25
- 85038519940
- Gemzar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2006, Accessed July 15
- Gemzar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2006. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020509s064lbl.pdf. Accessed July 15, 2011.
- (2011)

26
- 85038518294
- Fluorouracil injection [package insert]. Liberty Corner, NJ: GeneraMedix Inc.; 2007, July 15
- Fluorouracil injection [package insert]. Liberty Corner, NJ: GeneraMedix Inc.; 2007. http://www.bionichepharmausa.com/pdf/Bi-oniche_Fluorouracil_Single_PI.pdf. Accessed July 15, 2011.
- (2011)

27
- 85038506900
- Xeloda [package insert]. Nutley, NJ: Roche Laboratories; 2006, Accessed July 15
- Xeloda [package insert]. Nutley, NJ: Roche Laboratories; 2006. http://www.accessdata.fda.gov/drugsatfda_docs/ label/2005/020896s016lbl.pdf. Accessed July 15, 2011.
- (2011)

28
- 85038527162
- Cytarabine injection [package insert]. Lake Forest, IL: Hospira; 2008, Ac- cessed July 15
- Cytarabine injection [package insert]. Lake Forest, IL: Hospira; 2008. http://www.bdipharma.com/Product%20Inserts/hospira/Cytarabine483176PROMOWEB.f. Ac- cessed July 15, 2011.
- (2011)

29
- 85038524689
- Cytarabine. Wikipedia, Accessed July 15
- Cytarabine. Wikipedia. http://en.wikipedia.org/wiki/Cytarabine. Accessed July 15, 2011.
- (2011)

30
- 85038520083
- Purinethol [package insert]. Sellers-ville, PA: Gate Pharmaceuticals; 2003, Accessed July 15
- Purinethol [package insert]. Sellers-ville, PA: Gate Pharmaceuticals; 2003. http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/09053s024lbl.pdf. Accessed July 15, 2011.
- (2011)

31
- 0345491996
- Null association between prostate cancer and serum folate, vitamin B6, vitamin B12, and homocysteine
- Weinstein SJ, Hartman TJ, Stolzen- berg-Solomon R, et al. Null association between prostate cancer and serum folate, vitamin B6, vitamin B12, and homocysteine. Cancer Epidemiol Biomarkers Prev 2003;12:1271-1272.
- (2003) Cancer Epidemiol Biomarkers Prev , vol.12 , pp. 1271-1272
- Weinstein, S.J.¹ Hartman, T.J.² Stolzen-Berg-Solomon, R.³

32
- 85038486428
- Methotrexate [package insert]. Fort Lee, NJ: Dava Pharmaceuticals; 2009, Accessed July 15
- Methotrexate [package insert]. Fort Lee, NJ: Dava Pharmaceuticals; 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/008085s063lbl.pdf. Accessed July 15, 2011.
- (2011)

33
- 85038482729
- Alimta injection [package insert]. Indianapolis, IN: Eli Lilly and Company; 2004, Accessed July 15
- Alimta injection [package insert]. Indianapolis, IN: Eli Lilly and Company; 2004. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s018s021s022lbl.pdf. Accessed July 15, 2011.
- (2011)

34
- 85038480526
- Taxol injection [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011, Accessed July 15
- Taxol injection [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011. http://packageinserts.bms.com/pi/pi_taxol.pdf. Accessed July 15, 2011.
- (2011)

35
- 85038521184
- Abraxane [package insert]. Los Angeles, CA: Abraxis Oncology; 2009, Accessed July 15
- Abraxane [package insert]. Los Angeles, CA: Abraxis Oncology; 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021660s022lbl.pdf. Accessed July 15, 2011.
- (2011)

36
- 85038483606
- Taxotere [package insert]. Bridge-water, NJ: Sanofi-Aventis; 2010, Accessed July 15
- Taxotere [package insert]. Bridge-water, NJ: Sanofi-Aventis; 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020449s059lbl.pdf. Accessed July 15, 2011.
- (2011)

37
- 85038496160
- Ixempra [package insert]. Prince-ton, NJ: Bristol-Myers Squibb; 2010, Accessed July 15
- Ixempra [package insert]. Prince-ton, NJ: Bristol-Myers Squibb; 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022065s004s005lbl.pdf. Accessed July 15, 2011.
- (2011)

38
- 85038517972
- Drugs.com. Vincristine, Accessed July 15
- Drugs.com. Vincristine. http://www.drugs.com/pro/vincristine.html. Accessed July 15, 2011.
- (2011)

39
- 85038490023
- Drugs.com. Vinblastine, Accessed July 15
- Drugs.com. Vinblastine. http://www.drugs.com/pro/vinblastine.html. Accessed July 15, 2011.
- (2011)

40
- 85038496315
- Navelbine [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2002, Accessed July15
- Navelbine [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2002. http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20388S014lbl.pdf. Accessed July15, 2011.
- (2011)

41
- 0034923502
- DNA topoisomerases: Structure, function, and mechanism
- Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001;70:369-413.
- (2001) Annu Rev Biochem , vol.70 , pp. 369-413
- Champoux, J.J.¹

42
- 85038510634
- Camptosar [package insert]. New York, NY: Pfizer & Upjohn Company; 2009, Accessed July 15
- Camptosar [package insert]. New York, NY: Pfizer & Upjohn Company; 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020571s031s032s033s036s037lbl.pdf. Accessed July 15, 2011.
- (2011)

43
- 85038521399
- Hycamtin injection [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2006, Accessed July15
- Hycamtin injection [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2006. http://www.accessdata.fda.gov/drugsatf-da_docs/label/2010/020671s016s017lbl.pdf. Accessed July15, 2011.
- (2011)

44
- 85038507987
- Drugs.com. Etoposide, Accessed July 15
- Drugs.com. Etoposide. http://www.drugs.com/pro/etoposide.html. Accessed July 15, 2011.
- (2011)

45
- 85038496324
- Etopophos injection [package insert]. Princeton, NJ: Bristol-Myers Squibb, Accessed July 15
- Etopophos injection [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2011. http://packageinserts.bms.com/pi/pi_etopo-phos.pdf. Accessed July 15, 2011.
- (2011)

46
- 85038482289
- Novantrone injection [package insert]. Seattle, WA: Immunex Corporation; 2000, Accessed July 15
- Novantrone injection [package insert]. Seattle, WA: Immunex Corporation; 2000. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21120.pdf_Novantrone_Prn-tlbl.pdf. Accessed July 15, 2011.
- (2011)

47
- 85038500449
- Cosmegen injection [package insert]. Deerfield, IL: Ovation Pharmaceuticals, Inc.; 2008, Accessed July15
- Cosmegen injection [package insert]. Deerfield, IL: Ovation Pharmaceuticals, Inc.; 2008. http://www.accessdata.fda.gov/drugsatf-da_docs/label/2009/050682s025lbl.pdf. Accessed July15, 2011.
- (2011)

48
- 85038492591
- Doxorubicin HCl injection [pack- age insert]. New York, NY: Pharmacia & Upjohn Company, Accessed July 15
- Doxorubicin HCl injection [pack- age insert]. New York, NY: Pharmacia & Upjohn Company; 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050629s017lbl.pdf. Accessed July 15, 2011.
- (2010)

49
- 85038527241
- Ellence injection [package insert]. New York, NY: Pharmacia & Upjohn Company; 2005, Accessed July 15
- Ellence injection [package insert]. New York, NY: Pharmacia & Upjohn Company; 2005. http://www.accessdata.fda.gov/drug-satfda_docs/label/2005/50778s008lbl.pdf. Accessed July 15, 2011.
- (2011)

50
- 85038480281
- Blenoxane injection [package insert]. Princeton, NJ: Bristol-Myers Squibb Compa- ny; 2010, Accessed July 15
- Blenoxane injection [package insert]. Princeton, NJ: Bristol-Myers Squibb Compa- ny; 2010. http://www.accessdata.fda.gov/drug-satfda_docs/label/2010/050443s036lbl.pdf. Accessed July 15, 2011.
- (2011)

51
- 22044442973
- Tyrosine kinases as targets for cancer therapy
- Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-187.
- (2005) N Engl J Med , vol.353 , pp. 172-187
- Krause, D.S.¹ van Etten, R.A.²

52
- 85038512589
- Erbitux injection [package insert]. Princeton, NJ: Bristol-Myers Squibb Compa- ny; 2011, Accessed July 15
- Erbitux injection [package insert]. Princeton, NJ: Bristol-Myers Squibb Compa- ny; 2011. http://packageinserts.bms.com/pi/pi_erbitux.pdf. Accessed July 15, 2011.
- (2011)

53
- 85038525837
- Erbitux intravenous infusion [high-www.CommunityOncology.net Mechanisms of action of common anticancer drugs REVIEW lights of prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2011, Accessed July 15
- Erbitux intravenous infusion [high-www.CommunityOncology.net Mechanisms of action of common anticancer drugs REVIEW lights of prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125084s167lbl.pdf. Accessed July 15, 2011.
- (2011)

54
- 85038524136
- Herceptin intravenous infusion [package insert]. San Francisco, CA: Genentech, Inc.; 2006, Accessed July 15
- Herceptin intravenous infusion [package insert]. San Francisco, CA: Genentech, Inc.; 2006. http://www.accessdata.fda.gov/drugsatf-da_docs/label/2008/103792s5175lbl.pdf. Accessed July 15, 2011.
- (2011)

55
- 85038505057
- Tarceva [package insert]. San Francisco, CA: Genentech, Inc.; 2010, Accessed July 15
- Tarceva [package insert]. San Francisco, CA: Genentech, Inc.; 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf. Accessed July 15, 2011.
- (2011)

56
- 85038519679
- Avastin intravenous infusion [high-lights of prescribing information]. San Francisco, CA: Genentech, Inc.; 2010, Accessed July 15
- Avastin intravenous infusion [high-lights of prescribing information]. San Francisco, CA: Genentech, Inc.; 2010. http://www.gene.com/gene/products/information/pdf/avastinprescribing.pdf. Accessed July 15, 2011.
- (2011)

57
- 85038522046
- Avastin: VEGF Inhibition Summary, Accessed July 15
- Avastin: VEGF Inhibition Summary. http://www.avastin.com/avastin/hcp/overview/moa/targeting-vegf/index.m. Accessed July 15, 2011.
- (2011)

58
- 85038495795
- Avastin intravenous infusion [high-lights of prescribing information, final labeling text]. San Francisco, CA: Genentech, Inc.; 2009, Accessed July 25
- Avastin intravenous infusion [high-lights of prescribing information, final labeling text]. San Francisco, CA: Genentech, Inc.; 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0168lbl.pdf. Accessed July 25, 2011.
- (2011)

59
- 85038518422
- Nexavar [package insert]. West Haven, CT: Bayer Pharmaceuticals Corporation; 2007, Accessed July 15
- Nexavar [package insert]. West Haven, CT: Bayer Pharmaceuticals Corporation; 2007. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021923s004s005s006s007lbl.pdf. Accessed July 15, 2011.
- (2011)

60
- 85038524537
- Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009, Accessed July 15
- Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009. http://www.accessdata.fda.gov/drugsatf-da_docs/label/2009/021588s026s028lbl.pdf. Accessed July 15, 2011.
- (2011)

61
- 85038495394
- Sprycel [highlights of prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2010, Accessed July 15
- Sprycel [highlights of prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2010. http://packageinserts.bms.com/pi/pi_sprycel.pdf. Accessed July 15, 2010.
- (2010)

62
- 34248166041
- Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells
- Nam S, Williams A, Vultur A, et al. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther 2007;6:1400-1405.
- (2007) Mol Cancer Ther , vol.6 , pp. 1400-1405
- Nam, S.¹ Williams, A.² Vultur, A.³

63
- 85038501584
- Sprycel [highlights of prescribing information]. Princeton, NJ: Bristol-Myers Squibb, Company; 2008, Accessed July 15
- Sprycel [highlights of prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2008. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s005lbl.pdf. Accessed July 15, 2011. Volume 8 /Number 8
- (2011) , vol.8 , Issue.8

64
- 85038483010
- Torisel kit [highlights of prescribing information]. Philadelphia, PA: Wyeth, Pharmaceuticals Inc, Accessed July 15
- Torisel kit [highlights of prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022088s008lbl.pdf. Accessed July 15, 2011.
- (2010)

65
- 0022992658
- Hormonal agents and treatment of cancer
- Canellos GP. Hormonal agents and treatment of cancer. Urology 1986;27(1 suppl):4-8.
- (1986) Urology , vol.27 , Issue.1 SUPPL. , pp. 4-8
- Canellos, G.P.¹

66
- 85038524307
- Nolvadex [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2005, Accessed July 15
- Nolvadex [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2005. http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017970s054lbl.pdf. Accessed July 15, 2011.
- (2011)

67
- 2642531973
- Epigenetics in human disease and prospects for epigenetic therapy
- Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-463.
- (2004) Nature , vol.429 , pp. 457-463
- Egger, G.¹ Liang, G.² Aparicio, A.³ Jones, P.A.⁴

68
- 85038484719
- Zolinza [highlights of prescribing in- formation]. Whitehouse Station, NJ: Merck & Co, Inc.; 2009, Accessed July 15
- Zolinza [highlights of prescribing in- formation]. Whitehouse Station, NJ: Merck & Co., Inc.; 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021991s004lbl.pdf. Accessed July 15, 2011.
- (2011)

69
- 85038506925
- Vidaza injection [highlights of prescribing information]. Summit, NJ: Celgene Corporation, Accessed July 15
- Vidaza injection [highlights of prescribing information]. Summit, NJ: Celgene Corporation; 2008. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050794s011lbl.pdf. Accessed July 15, 2011.
- (2008)

70
- 67349253250
- Targeted agents and new directions in drug development
- eds, 4th ed. Philadelphia, PA: Churchill Livingstone Elsevier
- Abeloff MD, Armitage JO, Niederhuber JE, et al, eds. Targeted agents and new directions in drug development. In: Abeloff's Clinical Oncology, 4th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2008.
- (2008) Abeloff's Clinical Oncology
- Abeloff, M.D.¹ Armitage, J.O.² Niederhuber, J.E.³

71
- 85038521777
- Intron A injection [package insert]. Kenilworth, NJ: Schering Corporation, Accessed, July 15
- Intron A injection [package insert]. Kenilworth, NJ: Schering Corporation; 2007. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103132s5096lbl.pdf. Accessed July 15, 2011.
- (2007)

72
- 85038511473
- Roferon-A [package insert]. Nutley, NJ: Roche Pharmaceuticals, Accessed July 15
- Roferon-A [package insert]. Nutley, NJ: Roche Pharmaceuticals; 2003. http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/103145s5060LBL.pdf. Accessed July 15, 2011.
- (2003)

73
- 85038493372
- Rituxan injection [highlights of prescribing information; final labeling text]. San Francisco, CA: Genentech, Inc, Accessed, July 15
- Rituxan injection [highlights of prescribing information; final labeling text]. San Francisco, CA: Genentech, Inc.; 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf. Accessed July 15, 2011.
- (2010)

74
- 85038501172
- Revlimid [package insert]. Summit, NJ: Celgene Corporation; 2010, Accessed July 15
- Revlimid [package insert]. Summit, NJ: Celgene Corporation; 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021880s013lbl.pdf. Accessed July 15, 2011.
- (2011)

75
- 85038527337
- Targretin [package insert]. San Die-go, CA: Ligand Pharmaceuticals, Inc.; 1999, Accessed July 15
- Targretin [package insert]. San Die-go, CA: Ligand Pharmaceuticals, Inc.; 1999. http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21055lbl.pdf. Accessed July 15, 2011.
- (2011)

76
- 85038484914
- Vesanoid. Drugs.com Web site, Accessed July 20
- Vesanoid. Drugs.com Web site. http://www.drugs.com/monograph/vesanoid.html. Accessed July 20, 2011.
- (2011)

77
- 85038518899
- Vesanoid [package insert]. Nutley, NJ: Roche Laboratories Inc.; 2004, Accessed July 15
- Vesanoid [package insert]. Nutley, NJ: Roche Laboratories Inc.; 2004. http://www.accessdata.fda.gov./drugsatfda_docs/label/2004/20438s004lbl.pdf. Accessed July 15, 2011.
- (2011)

78
- 85038520253
- Trisenox injection [package insert]. West Chester, PA: Cephalon; 2010, Accessed July 15
- Trisenox injection [package insert]. West Chester, PA: Cephalon; 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021248s009lbl.pdf. Accessed July 15, 2011.
- (2011)

79
- 0037099645
- Mechanisms of action of arsenic trioxide
- Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of ar- senic trioxide. Cancer Res 2002;62:3893-3903.
- (2002) Cancer Res , vol.62 , pp. 3893-3903
- Miller, W.H.¹ Schipper, H.M.² Lee, J.S.³ Singer, J.⁴ Waxman, S.⁵

80
- 85038503717
- Asparaginase. Wikipedia, 2011, Accessed July 15
- Asparaginase. Wikipedia, 2011. http://en.wikipedia.org/wiki/Asparaginase. Accessed July 15, 2011.
- (2011)

81
- 85038483216
- Elspar [package insert]. West Point, PA: Merck & Co., Inc.; 2000, Accessed July 15
- Elspar [package insert]. West Point, PA: Merck & Co., Inc.; 2000. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088651.pdf. Accessed July 15, 2011.
- (2011)

82
- 85038525222
- Velcade. MediLexicon, Accessed July 15
- Velcade. MediLexicon. http://www.medilexicon.com/drugs/velcade.php. Accessed July 15, 2011.
- (2011)

83
- 85038487435
- Velcade [highlights of prescribing information]. Cambridge, MA: Millen- nium Pharmaceuticals, Inc, Accessed July 15
- Velcade [highlights of prescribing information]. Cambridge, MA: Millen- nium Pharmaceuticals, Inc.; 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021602s019s020lbl.pdf. Accessed July 15, 2011.
- (2009)

84
- 0029803181
- What clinical information do doctors need?
- Smith R. What clinical information do doctors need? Br Med J 1996;313:1062-1068.
- (1996) Br Med J , vol.313 , pp. 1062-1068
- Smith, R.¹

85
- 49249095165
- Current and future utilization of ser- vices from medical oncologists
- Warren JL, Mariotto AB, Meekins A, et al. Current and future utilization of ser- vices from medical oncologists. J Clin Oncol 2008;26:3242-3247.
- (2008) J Clin Oncol , vol.26 , pp. 3242-3247
- Warren, J.L.¹ Mariotto, A.B.² Meekins, A.³

86
- 85038491316
- National Comprehensive Cancer Network Web site, Accessed July 15
- National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed July 15, 2011.
- (2011)

87
- 79952847008
- Use of electronic medical records by ambulatory care providers: United States, 2006
- Hing E, Hall MJ, Ashman JJ. Use of electronic medical records by ambulatory care providers: United States, 2006. Natl Health Stat Report 2010;22:1-21.
- (2010) Natl Health Stat Report , vol.22 , pp. 1-21
- Hing, E.¹ Hall, M.J.² Ashman, J.J.³

88
- 84872820759
- Electronic medical record use by office-based physicians and their practices: United States, 2007
- Hing E, Hsiao CJ. Electronic medical record use by office-based physicians and their practices: United States, 2007. Natl Health Stat Report 2010:23:1-11.
- (2010) Natl Health Stat Report , vol.23 , pp. 1-11
- Hing, E.¹ Hsiao, C.J.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.